OPKO Health (NASDAQ:OPK) Given Buy Rating at HC Wainwright

OPKO Health (NASDAQ:OPK)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They presently have a $3.00 target price on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 67.60% from the company’s previous close. HC Wainwright also issued estimates for OPKO Health’s Q2 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.30) EPS.

Several other research analysts have also commented on the stock. StockNews.com raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research note on Monday, March 3rd. Barrington Research reaffirmed an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research note on Wednesday, March 12th.

OPKO Health Trading Down 1.1 %

Shares of OPK opened at $1.79 on Wednesday. The company’s fifty day moving average is $1.63 and its 200 day moving average is $1.57. OPKO Health has a fifty-two week low of $0.86 and a fifty-two week high of $2.04. The stock has a market capitalization of $1.20 billion, a PE ratio of -9.42 and a beta of 1.70. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.09. The company had revenue of $183.60 million for the quarter, compared to analysts’ expectations of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. Sell-side analysts expect that OPKO Health will post -0.25 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Phillip Md Et Al Frost bought 500,000 shares of the stock in a transaction dated Wednesday, January 15th. The stock was purchased at an average cost of $1.48 per share, with a total value of $740,000.00. Following the completion of the purchase, the chief executive officer now owns 213,036,477 shares of the company’s stock, valued at $315,293,985.96. This trade represents a 0.24 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Over the last ninety days, insiders purchased 964,971 shares of company stock valued at $1,493,692. 47.26% of the stock is currently owned by company insiders.

Institutional Trading of OPKO Health

A number of large investors have recently made changes to their positions in OPK. Rubric Capital Management LP boosted its stake in shares of OPKO Health by 9.6% during the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock valued at $72,573,000 after purchasing an additional 4,284,336 shares during the period. Millennium Management LLC raised its holdings in shares of OPKO Health by 85.3% in the fourth quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock valued at $6,745,000 after acquiring an additional 2,112,382 shares in the last quarter. Lazard Asset Management LLC raised its holdings in shares of OPKO Health by 143.6% in the fourth quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company’s stock valued at $3,746,000 after acquiring an additional 1,502,342 shares in the last quarter. Altshuler Shaham Ltd bought a new stake in shares of OPKO Health in the fourth quarter valued at about $2,082,000. Finally, Norges Bank bought a new stake in shares of OPKO Health in the fourth quarter valued at about $1,657,000. 64.63% of the stock is owned by hedge funds and other institutional investors.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.